← Back to Screener
Edwards Lifesciences Corp (EW)
Price$81.44
Favorite Metrics
Price vs S&P 500 (26W)4.75%
Price vs S&P 500 (4W)-8.85%
Market Capitalization$47.12B
P/E Ratio (Annual)43.89x
All Metrics
P/CF (Annual)29.54x
Book Value / Share (Quarterly)$17.80
P/TBV (Annual)5.37x
Revenue Growth (3Y)4.08%
Cash Flow / Share (Quarterly)$2.30
Price vs S&P 500 (YTD)-8.40%
Gross Margin (TTM)78.01%
Net Profit Margin (TTM)17.69%
EPS (TTM)$1.83
10-Day Avg Trading Volume5.36M
EPS Excl Extra (TTM)$1.83
Revenue Growth (5Y)6.70%
EPS (Annual)$1.83
ROI (Annual)9.82%
Gross Margin (Annual)78.01%
Net Profit Margin (5Y Avg)34.96%
Cash / Share (Quarterly)$7.28
P/E Basic Excl Extra (TTM)43.89x
Revenue Growth QoQ (YoY)13.26%
EPS Growth (5Y)7.06%
P/E Normalized (Annual)43.89x
ROA (Last FY)7.84%
Revenue Growth TTM (YoY)6.00%
EBITD / Share (TTM)$2.19
ROE (5Y Avg)25.04%
Operating Margin (TTM)18.41%
Cash Flow / Share (Annual)$2.30
P/B Ratio4.56x
P/B Ratio (Quarterly)4.79x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)7.38x
Net Interest Coverage (TTM)3.15x
ROA (TTM)8.03%
EPS Growth QoQ (YoY)-75.94%
EV / EBITDA (TTM)34.95x
EPS Incl Extra (Annual)$1.83
Current Ratio (Annual)3.72x
Quick Ratio (Quarterly)3.02x
3-Month Avg Trading Volume4.33M
52-Week Price Return13.85%
EV / Free Cash Flow (Annual)33.54x
P/E Incl Extra (TTM)43.89x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$15.86
P/S Ratio (Annual)7.77x
Asset Turnover (Annual)0.44x
52-Week High$87.89
Operating Margin (5Y Avg)25.36%
EPS Excl Extra (Annual)$1.83
CapEx CAGR (5Y)-8.57%
Tangible BV CAGR (5Y)16.77%
26-Week Price Return11.64%
Quick Ratio (Annual)3.02x
13-Week Price Return-3.61%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)3.72x
Enterprise Value$44,778.167
Revenue / Share Growth (5Y)8.33%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)19.43%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.21x
Pretax Margin (Annual)20.98%
Cash / Share (Annual)$7.28
3-Month Return Std Dev26.82%
Gross Margin (5Y Avg)74.05%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)4.94%
EBITDA Interim CAGR (5Y)-24.01%
ROE (Last FY)10.38%
Net Interest Coverage (Annual)110.03x
EPS Basic Excl Extra (Annual)$1.83
P/FCF (TTM)35.29x
Receivables Turnover (TTM)9.57x
EV / Free Cash Flow (TTM)33.54x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$1.83
Receivables Turnover (Annual)9.57x
ROI (TTM)9.85%
P/S Ratio (TTM)7.77x
Pretax Margin (5Y Avg)26.61%
Revenue / Share (Annual)$10.36
Tangible BV / Share (Annual)$15.86
Forward P/E27.39x
Free OCF CAGR (5Y)15.59%
Price vs S&P 500 (52W)-20.78%
P/E Ratio (TTM)43.89x
EPS Growth TTM (YoY)-73.77%
Year-to-Date Return-4.47%
5-Day Price Return4.14%
EPS Normalized (Annual)$1.83
ROA (5Y Avg)18.17%
Net Profit Margin (Annual)17.69%
Month-to-Date Return1.70%
Cash Flow / Share (TTM)$2.57
EBITD / Share (Annual)$2.18
EPS Growth (3Y)-9.08%
Operating Margin (Annual)18.41%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)29.54x
ROI (5Y Avg)23.14%
P/E Excl Extra (TTM)43.89x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$1.83
P/TBV (Quarterly)5.37x
P/B Ratio (Annual)4.79x
Inventory Turnover (TTM)1.21x
Pretax Margin (TTM)20.98%
Book Value / Share (Annual)$17.80
Price vs S&P 500 (13W)-5.99%
Net Margin Growth (5Y)-1.18%
Beta0.86x
P/FCF (Annual)35.29x
Revenue / Share (TTM)$10.45
ROE (TTM)10.42%
52-Week Low$68.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.98
3.98
3.98
3.98
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
AVNSAvanos Medical, Inc. | 1.64x | -0.38% | 50.47% | -8.78% | $24.64 |
About
Edwards Lifesciences is a global leader in medical devices for treating structural heart disease, specializing in surgical tissue heart valves and transcatheter valve replacement technologies. Spun off from Baxter International in 2000, the company has established dominant market positions across aortic, mitral, and tricuspid valve solutions. With approximately 60% of revenues from international markets, Edwards benefits from strong geographic diversification in the growing structural heart disease treatment sector.